Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NOTV 
Inotiv Inc (NOTV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NOTV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.5
1 Year Target Price $5.5
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.62% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 60.46M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 3 | Beta 4.01 | 52 Weeks Range 1.15 - 6.48 | Updated Date 08/29/2025 |
52 Weeks Range 1.15 - 6.48 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When After Market | Estimate -0.3935 | Actual -0.51 |
Profitability
Profit Margin -15.63% | Operating Margin (TTM) -4.23% |
Management Effectiveness
Return on Assets (TTM) -2.88% | Return on Equity (TTM) -48.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 499714141 | Price to Sales(TTM) 0.12 |
Enterprise Value 499714141 | Price to Sales(TTM) 0.12 | ||
Enterprise Value to Revenue 0.99 | Enterprise Value to EBITDA 23.57 | Shares Outstanding 34354300 | Shares Floating 31212211 |
Shares Outstanding 34354300 | Shares Floating 31212211 | ||
Percent Insiders 11.31 | Percent Institutions 25.41 |
Upturn AI SWOT
Inotiv Inc
Company Overview
History and Background
Inotiv Inc., formerly Bioanalytical Systems, Inc. (BASi), was founded in 1974. Initially focused on bioanalytical services, the company has expanded through acquisitions to provide a broader range of preclinical and analytical research services. Key milestones include strategic acquisitions to enhance its service offerings and expand its geographic reach.
Core Business Areas
- Discovery and Safety Assessment: Provides a broad range of preclinical discovery and safety assessment services, including toxicology, pathology, and pharmacology studies.
- Analytical Solutions: Offers analytical chemistry services, including method development, validation, and sample analysis.
- Research Models and Services (RMS): Breeding and distribution of research models (animals) and associated services.
Leadership and Structure
Robert Leasure Jr. is the President and Chief Executive Officer. The company has a typical corporate structure with various departments including operations, finance, and research and development. A board of directors oversees the overall strategy and performance.
Top Products and Market Share
Key Offerings
- Toxicology Studies: Comprehensive toxicology studies for pharmaceutical, biotechnology, and chemical companies. Market share data is fragmented, but major competitors include Charles River Laboratories and Labcorp Drug Development. Revenue data is not publicly disaggregated per service but toxicology studies contribute significantly to overall revenue.
- Pharmacokinetics/Pharmacodynamics (PK/PD): PK/PD studies to assess drug absorption, distribution, metabolism, and excretion. Competitors include Charles River Laboratories and Wuxi AppTec. Revenue data is not publicly disaggregated per service but PK/PD studies contribute significantly to overall revenue.
- Research Models: Breeding and sale of laboratory animals used in drug development and research. Competitors include Charles River Laboratories and Envigo. Revenue data is not publicly disaggregated per service but is a significant component of overall revenue.
Market Dynamics
Industry Overview
The preclinical contract research organization (CRO) market is growing due to increasing R&D spending by pharmaceutical and biotechnology companies and the need for specialized expertise. Increased regulatory scrutiny also drives demand for preclinical testing services.
Positioning
Inotiv Inc. is positioned as a mid-sized CRO providing integrated preclinical services. Its competitive advantage lies in its broad service offering and specialized expertise.
Total Addressable Market (TAM)
The global preclinical CRO market is estimated to be around $9 billion. Inotiv Inc. is positioned to capture a portion of this market through its comprehensive service offerings.
Upturn SWOT Analysis
Strengths
- Comprehensive preclinical service offering
- Experienced scientific staff
- Strategic acquisitions to expand capabilities
- Established relationships with pharmaceutical and biotechnology companies
Weaknesses
- High debt levels
- Integration challenges from acquisitions
- Dependence on key personnel
- Vulnerability to economic downturns
Opportunities
- Increasing demand for preclinical CRO services
- Expansion into new geographic markets
- Development of new service offerings
- Strategic partnerships with pharmaceutical and biotechnology companies
Threats
- Intense competition from larger CROs
- Economic downturns affecting R&D spending
- Regulatory changes impacting preclinical testing requirements
- Loss of key personnel
Competitors and Market Share
Key Competitors
- CRL
- IQV
- WUXI
Competitive Landscape
Inotiv Inc. faces intense competition from larger CROs with greater resources and market share. Its competitive advantage lies in its specialized expertise and integrated service offerings.
Major Acquisitions
Bolder BioPATH, Inc.
- Year: 2021
- Acquisition Price (USD millions): 14.5
- Strategic Rationale: Expanded capabilities in pharmacology and drug discovery.
Envigo RMS Holding Corp.
- Year: 2021
- Acquisition Price (USD millions): 545
- Strategic Rationale: Significant expansion into research models and services market, diversifying revenue streams and expanding client base. This also faced scrutiny due to animal welfare violations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by acquisitions and organic expansion of service offerings.
Future Projections: Future growth is expected to be driven by increasing demand for preclinical CRO services and strategic acquisitions. Analyst estimates vary.
Recent Initiatives: Recent initiatives include acquisitions to expand service offerings and geographic reach, as well as investments in new technologies and infrastructure.
Summary
Inotiv Inc. is a mid-sized CRO with a comprehensive preclinical service offering. Its strength lies in its integrated services and strategic acquisitions. However, high debt levels and integration challenges pose significant risks. The company needs to carefully manage its debt and ensure smooth integration of acquired companies to capitalize on market opportunities and maintain a competitive edge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is based on available information and estimates. It is not financial advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inotiv Inc
Exchange NASDAQ | Headquaters West Lafayette, IN, United States | ||
IPO Launch date 1997-11-25 | President, CEO & Director Mr. Robert W. Leasure Jr. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1977 | Website https://www.inotiv.com |
Full time employees 1977 | Website https://www.inotiv.com | ||
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. It operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.